Return to Results

Pivotal/Phase III Multicentered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 Solution (Zuragen), and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chr

new search

Trial Conditions
  • End Stage Renal Disease
What is the purpose of this trial?

The purpose of this study is to determine if AAT-023 (Zuragen) solution is superior to Heparin in preventing Catheter Related Blood Stream Infections for End Stage Renal Disease patients.

Date & Status

Active, not recruiting

Who can Participate?


18 and older



Inclusion Criteria:

1. End Stage Renal Disease 18 yrs or older.

2. CVCD with average dialysis flow rate over 300 mL/min for three most recent visits.

3. Expectation by Investigator that CVCD may be needed for up to 26 weeks.

4. Dialysis catheter is of three types a) single body with single entry and exit, b)
single body with split ends, c) twin catheter with one catheter for removal of blood
and another for return.

5. Kt/V >1.1 or equivalent URR

6. Negative serum pregnancy unless surgically sterile or post menopausal for >1yr.

7. Negative blood culture result from pre-enrollment blood sample draw.

8. Ability of patient to sign and understand the informed consent.

9. Most recent lab results don't indicate hypocalcemia (<7mg/dL) or thrombocytopenia

10. Avg. systolic blood pressure >90 mmHg as measured during the most recent three
dialysis treatments.

11. Lack of signs of current blood stream infection at the beginning of the prior three
dialysis treatments.

Exclusion Criteria:

1. A known Heparin allergy or a history of type 2 (antibody mediated) Heparin-induced

2. Active bleeding from any site or a documented positive stool hemocult test within 28
days of enrollment in study.

3. Bloodstream infection,exit site infection or any infection requiring antibiotic use
within 14 days of enrollment for any antibiotic listed in section 4.2.3 or within 30
days of enrollment for Vancomycin or any other antibiotic not listed in section 4.2.3
of the protocol

4. Inability to comply with the conditions of, or complete the protocol in the opinion
of the Investigator.

5. Pregnant or breast feeding.

6. Documented allergy to sodium citrate, methylene blue, methyl/paraben and/or propyl

7. Documented chronic intrinsic coagulopathy evidenced by persistently and significantly
elevated Prothrombin (INR>3), Partial Thromboplastin Time (PTT>60 seconds), or
thrombocytopenia (platlet count <20,000/mm).

8. Malignancy requiring chemotherapy or radiation treatment within 180 days of

9. Documented requirement for >5,000 units of Heparin per catheter lumen to maintain
catheter patency (with decrease in blood flow demonstrated at 5,000 units per lumen
Heparin catheter lock) with current catheter.

10. Contraindications to citrate or taking drugs that may interact with citrate.

11. Documented history of glucose-6-phosphate dehydrogenase deficiency (G6PD or
Drug-induced methemoglobinemia).

12. Participation in another research study.

13. Co-morbidities, such as HIV, active hepatitis or recent transplants, that in the
opinion of the Investigator, may increase the risk associated with study
participation or may interfere with the interpretation of study results and would
make the subject inappropriate for entry into this study.

14. Unknown priming volume of catheter lumens.

15. Redness of over 1 cm diameter or pus around the catheter exit site.

Gender: Both
  • St. Elizabeth's Medical Center - Active, not recruiting
Trial Interventions
  • AAT-023 solution (Zuragen)
  • Heparin
Other Information

Sponsor: Ash Access Technology
Phase: Phase 3
Trial ID: NCT00628680
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2015 Steward Health Care
Connect Healthcare Panacea CMS Solutions